ES2664229T3 - Composiciones y métodos de biomatriz-PDGF para el tratamiento de lesiones del manguito rotador - Google Patents
Composiciones y métodos de biomatriz-PDGF para el tratamiento de lesiones del manguito rotador Download PDFInfo
- Publication number
- ES2664229T3 ES2664229T3 ES07796636.4T ES07796636T ES2664229T3 ES 2664229 T3 ES2664229 T3 ES 2664229T3 ES 07796636 T ES07796636 T ES 07796636T ES 2664229 T3 ES2664229 T3 ES 2664229T3
- Authority
- ES
- Spain
- Prior art keywords
- pdgf
- composition
- use according
- tendon
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 212
- 238000011282 treatment Methods 0.000 title claims abstract description 43
- 208000024288 Rotator Cuff injury Diseases 0.000 title claims description 25
- 238000000034 method Methods 0.000 title description 97
- 210000002435 tendon Anatomy 0.000 claims abstract description 259
- 239000011159 matrix material Substances 0.000 claims abstract description 159
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 154
- 239000000463 material Substances 0.000 claims abstract description 96
- 102000008186 Collagen Human genes 0.000 claims abstract description 79
- 108010035532 Collagen Proteins 0.000 claims abstract description 79
- 229920001436 collagen Polymers 0.000 claims abstract description 79
- 239000011230 binding agent Substances 0.000 claims abstract description 60
- 239000000243 solution Substances 0.000 claims description 122
- 239000002245 particle Substances 0.000 claims description 47
- 210000004095 humeral head Anatomy 0.000 claims description 27
- 210000002758 humerus Anatomy 0.000 claims description 25
- 238000002513 implantation Methods 0.000 claims description 23
- 239000001506 calcium phosphate Substances 0.000 claims description 20
- 108010081589 Becaplermin Proteins 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 10
- -1 PDGF -DD Proteins 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 230000032798 delamination Effects 0.000 claims description 8
- 239000007974 sodium acetate buffer Substances 0.000 claims description 7
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 5
- 108010000685 platelet-derived growth factor AB Proteins 0.000 claims description 5
- 230000001054 cortical effect Effects 0.000 claims description 4
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims description 4
- 230000008467 tissue growth Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 213
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 213
- 241001465754 Metazoa Species 0.000 description 95
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 82
- 210000000513 rotator cuff Anatomy 0.000 description 37
- 238000001356 surgical procedure Methods 0.000 description 36
- 238000012360 testing method Methods 0.000 description 34
- 230000008439 repair process Effects 0.000 description 32
- 210000003205 muscle Anatomy 0.000 description 19
- 102000012422 Collagen Type I Human genes 0.000 description 18
- 108010022452 Collagen Type I Proteins 0.000 description 18
- 238000003780 insertion Methods 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 230000037431 insertion Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 15
- 235000011010 calcium phosphates Nutrition 0.000 description 14
- 239000008351 acetate buffer Substances 0.000 description 12
- 230000006833 reintegration Effects 0.000 description 12
- 229910000389 calcium phosphate Inorganic materials 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000035876 healing Effects 0.000 description 11
- 238000002595 magnetic resonance imaging Methods 0.000 description 11
- 239000013543 active substance Substances 0.000 description 10
- 230000002980 postoperative effect Effects 0.000 description 10
- 210000000323 shoulder joint Anatomy 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 8
- 229960001139 cefazolin Drugs 0.000 description 8
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 230000002787 reinforcement Effects 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004873 anchoring Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 210000000852 deltoid muscle Anatomy 0.000 description 6
- 230000009969 flowable effect Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 5
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 210000002659 acromion Anatomy 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 229940112869 bone morphogenetic protein Drugs 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000002695 general anesthesia Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 4
- 241001631457 Cannula Species 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- 206010043248 Tendon rupture Diseases 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000003041 ligament Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 229920001432 poly(L-lactide) Polymers 0.000 description 4
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 4
- 229920001610 polycaprolactone Polymers 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001227713 Chiron Species 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 102000000503 Collagen Type II Human genes 0.000 description 3
- 108010041390 Collagen Type II Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 210000001361 achilles tendon Anatomy 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 3
- 229960001736 buprenorphine Drugs 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004023 fresh frozen plasma Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000002138 osteoinductive effect Effects 0.000 description 3
- 230000001009 osteoporotic effect Effects 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 239000004633 polyglycolic acid Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229920000049 Carbon (fiber) Polymers 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001653121 Glenoides Species 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 206010037688 Q fever Diseases 0.000 description 2
- 241000322863 Quadraceps Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003160 anti-catabolic effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 239000011449 brick Substances 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- ZBZJARSYCHAEND-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydrate Chemical compound O.[Ca+2].OP(O)([O-])=O.OP(O)([O-])=O ZBZJARSYCHAEND-UHFFFAOYSA-L 0.000 description 2
- 239000004917 carbon fiber Substances 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium phosphate dihydrate Substances O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 208000030175 lameness Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910000150 monocalcium phosphate Inorganic materials 0.000 description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 229910000392 octacalcium phosphate Inorganic materials 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000000426 patellar ligament Anatomy 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000004261 periodontium Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920001042 poly(δ-valerolactone) Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920001299 polypropylene fumarate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YIGWVOWKHUSYER-UHFFFAOYSA-F tetracalcium;hydrogen phosphate;diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O YIGWVOWKHUSYER-UHFFFAOYSA-F 0.000 description 2
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 2
- 239000003634 thrombocyte concentrate Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QHQZEEGNGSZBOL-UHFFFAOYSA-N 2-(aminomethyl)-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(CO)(CO)CO QHQZEEGNGSZBOL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- NYEZZYQZRQDLEH-UHFFFAOYSA-N 2-ethyl-4,5-dihydro-1,3-oxazole Chemical compound CCC1=NCCO1 NYEZZYQZRQDLEH-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 108010027258 GEM 21S Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000014015 Growth Differentiation Factors Human genes 0.000 description 1
- 108010050777 Growth Differentiation Factors Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101001003146 Mus musculus Interleukin-11 receptor subunit alpha-1 Proteins 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 206010039227 Rotator cuff syndrome Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000018286 Shoulder injury Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- ROPDWRCJTIRLTR-UHFFFAOYSA-L calcium metaphosphate Chemical compound [Ca+2].[O-]P(=O)=O.[O-]P(=O)=O ROPDWRCJTIRLTR-UHFFFAOYSA-L 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical class [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- KBQXDPRNSDVNLB-UHFFFAOYSA-L calcium;carbonic acid;hydrogen phosphate Chemical compound [Ca+2].OC(O)=O.OP([O-])([O-])=O KBQXDPRNSDVNLB-UHFFFAOYSA-L 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229940017578 naxcel Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000001422 normality test Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000004820 osteoconduction Effects 0.000 description 1
- 230000004819 osteoinduction Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000008375 physiological alteration Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920006209 poly(L-lactide-co-D,L-lactide) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229940116157 regranex Drugs 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960002901 sodium glycerophosphate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000003232 water-soluble binding agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0401—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/08—Muscles; Tendons; Ligaments
- A61F2/0811—Fixation devices for tendons or ligaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0401—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
- A61B2017/044—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors with a threaded shaft, e.g. screws
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0401—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
- A61B2017/0464—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors for soft tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/08—Muscles; Tendons; Ligaments
- A61F2/0811—Fixation devices for tendons or ligaments
- A61F2002/0847—Mode of fixation of anchor to tendon or ligament
- A61F2002/0858—Fixation of tendon or ligament between anchor and bone, e.g. interference screws, wedges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/08—Muscles; Tendons; Ligaments
- A61F2/0811—Fixation devices for tendons or ligaments
- A61F2002/0876—Position of anchor in respect to the bone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/10—Materials or treatment for tissue regeneration for reconstruction of tendons or ligaments
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Rehabilitation Therapy (AREA)
- Vascular Medicine (AREA)
- Medical Informatics (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81787406P | 2006-06-30 | 2006-06-30 | |
| US817874P | 2006-06-30 | ||
| PCT/US2007/015345 WO2008005427A2 (en) | 2006-06-30 | 2007-07-02 | Pdgf-biomatrix compositions and methods for treating rotator cuff injuries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2664229T3 true ES2664229T3 (es) | 2018-04-18 |
Family
ID=38821246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07796636.4T Active ES2664229T3 (es) | 2006-06-30 | 2007-07-02 | Composiciones y métodos de biomatriz-PDGF para el tratamiento de lesiones del manguito rotador |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US9642891B2 (enExample) |
| EP (2) | EP2049145B1 (enExample) |
| JP (1) | JP5484047B2 (enExample) |
| AU (1) | AU2007269712B2 (enExample) |
| CA (1) | CA2656278C (enExample) |
| ES (1) | ES2664229T3 (enExample) |
| WO (1) | WO2008005427A2 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7473678B2 (en) * | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| WO2007061889A2 (en) | 2005-11-17 | 2007-05-31 | Biomimetic Therapeutics, Inc. | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
| EP1991282B1 (en) * | 2006-02-09 | 2013-06-19 | BioMimetic Therapeutics, LLC | Compositions and methods for treating bone |
| CA2656278C (en) | 2006-06-30 | 2016-02-09 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating rotator cuff injuries |
| US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| US8444758B2 (en) | 2006-10-19 | 2013-05-21 | Eastman Chemical Company | Low voc additives for extending the wet edge and open time of aqueous coatings |
| US8106008B2 (en) | 2006-11-03 | 2012-01-31 | Biomimetic Therapeutics, Inc. | Compositions and methods for arthrodetic procedures |
| WO2008103690A2 (en) * | 2007-02-20 | 2008-08-28 | Biomimetic Therapeutics, Inc. | Prevention and treatment for osteonecrosis and osteoradionecrosis of the jaw using pdgf and a bone matrix |
| EP2124831B1 (en) | 2007-03-15 | 2016-07-06 | Ortho-Space Ltd. | Prosthetic devices |
| ES2422259T3 (es) * | 2008-02-07 | 2013-09-10 | Biomimetic Therapeutics Inc | Composiciones para la osteogénesis por distracción |
| CN102098984B (zh) | 2008-05-14 | 2017-06-23 | 史密夫和内修有限公司 | 关节镜下二头肌腱固定术修复装置 |
| KR20110067035A (ko) * | 2008-09-09 | 2011-06-20 | 바이오미메틱 세라퓨틱스, 인크. | 건 및 인대 손상의 치료를 위한 혈소판-유래 성장 인자 조성물 및 방법 |
| EP2385807A2 (en) | 2008-12-09 | 2011-11-16 | Smith & Nephew, Inc. | Tissue repair assembly |
| US8858606B2 (en) | 2008-12-09 | 2014-10-14 | Smith & Nephew, Inc. | Tissue repair assembly |
| WO2010081029A1 (en) | 2009-01-08 | 2010-07-15 | Rotation Medical, Inc. | Implantable tendon protection systems and related kits and methods |
| US20100211174A1 (en) * | 2009-02-19 | 2010-08-19 | Tyco Healthcare Group Lp | Method For Repairing A Rotator Cuff |
| AU2010221089A1 (en) * | 2009-03-05 | 2011-09-15 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects |
| US9179910B2 (en) | 2009-03-20 | 2015-11-10 | Rotation Medical, Inc. | Medical device delivery system and method |
| US8231653B2 (en) * | 2009-03-31 | 2012-07-31 | Arthrex, Inc. | Method of forming knotless double row construct with graft or patch fixed under repair site |
| US12471975B2 (en) | 2009-06-04 | 2025-11-18 | Rotation Medical, Inc. | Methods and apparatus for deploying sheet-like materials |
| JP5718912B2 (ja) | 2009-06-04 | 2015-05-13 | ローテーション メディカル インコーポレイテッドＲｏｔａｔｉｏｎ Ｍｅｄｉｃａｌ，Ｉｎｃ． | 移植物搬送システム及び搬送システムを準備する方法 |
| JP5662427B2 (ja) | 2009-06-04 | 2015-01-28 | ローテーション メディカル インコーポレイテッドＲｏｔａｔｉｏｎ Ｍｅｄｉｃａｌ，Ｉｎｃ． | 目的の組織にシート状材料を固定するための装置 |
| US20120282235A1 (en) * | 2009-09-25 | 2012-11-08 | Ohashi Kevin L | Implantable patch and surgical kit for preparation thereof |
| US8690960B2 (en) * | 2009-11-24 | 2014-04-08 | Covidien Lp | Reinforced tissue patch |
| CN107080834A (zh) * | 2010-02-22 | 2017-08-22 | 生物模拟治疗有限责任公司 | 用于治疗腱病的血小板衍生生长因子组合物和方法 |
| US9198750B2 (en) | 2010-03-11 | 2015-12-01 | Rotation Medical, Inc. | Tendon repair implant and method of arthroscopic implantation |
| WO2012105224A1 (ja) * | 2011-01-31 | 2012-08-09 | オリンパス株式会社 | ワクチン・アジュバント |
| CA2825918C (en) | 2011-02-15 | 2018-08-07 | Rotation Medical, Inc. | Methods and apparatus for delivering and positioning sheet-like materials |
| WO2012145059A1 (en) | 2011-02-15 | 2012-10-26 | Rotation Medical, Inc. | Methods and apparatus for fixing sheet-like materials to a target tissue |
| US9289307B2 (en) | 2011-10-18 | 2016-03-22 | Ortho-Space Ltd. | Prosthetic devices and methods for using same |
| WO2013062994A1 (en) | 2011-10-25 | 2013-05-02 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating full thickness burn injuries |
| US20130108683A1 (en) * | 2011-10-25 | 2013-05-02 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating partial and full thickness wounds and injuries |
| US9107661B2 (en) | 2011-12-19 | 2015-08-18 | Rotation Medical, Inc. | Fasteners and fastener delivery devices for affixing sheet-like materials to bone or tissue |
| WO2013096224A1 (en) | 2011-12-19 | 2013-06-27 | Rotation Medical, Inc. | Fasteners for affixing sheet -like materials to bone or tissue |
| AU2012355433B2 (en) | 2011-12-19 | 2016-10-20 | Rotation Medical, Inc. | Apparatus and method for forming pilot holes in bone and delivering fasteners therein for retaining an implant |
| US9370356B2 (en) | 2011-12-19 | 2016-06-21 | Rotation Medical, Inc. | Fasteners and fastener delivery devices for affixing sheet-like materials to bone or tissue |
| EP2797532B1 (en) | 2011-12-29 | 2016-04-06 | Rotation Medical, Inc. | Apparatus for delivering and positioning sheet-like materials in surgery |
| WO2013101641A2 (en) | 2011-12-29 | 2013-07-04 | Rotation Medical, Inc. | Anatomical location markers and methods of use in positioning sheet-like materials during surgery |
| WO2013101640A1 (en) | 2011-12-29 | 2013-07-04 | Rotation Medical, Inc. | Guidewire having a distal fixation member for delivering and positioning sheet-like materials in surgery |
| US9345577B2 (en) * | 2013-03-14 | 2016-05-24 | Microaire Surgical Instruments Llc | Balloon implant device |
| CA2945821C (en) | 2014-05-09 | 2018-09-04 | Rotation Medical, Inc. | Medical implant delivery system for sheet-like implant |
| EP3166624B1 (en) | 2014-07-09 | 2020-06-03 | Mayo Foundation for Medical Education and Research | Treating rotator cuff conditions |
| MX2017004520A (es) * | 2014-10-14 | 2018-03-15 | Lynch Samuel | Composiciones para tratar heridas. |
| EP3215025B1 (en) | 2014-11-04 | 2020-12-23 | Rotation Medical, Inc. | Medical implant delivery system |
| US10675019B2 (en) | 2014-11-04 | 2020-06-09 | Rotation Medical, Inc. | Medical implant delivery system and related methods |
| EP4275620A3 (en) | 2014-11-04 | 2024-01-17 | Rotation Medical, Inc. | Medical implant delivery system |
| WO2016175967A1 (en) * | 2015-04-30 | 2016-11-03 | Encore Medical, L.P. | Soft tissue repair using a porous coating implant |
| US10898228B2 (en) | 2015-05-06 | 2021-01-26 | Rotation Medical, Inc. | Medical implant delivery system and related methods |
| WO2016205186A1 (en) | 2015-06-15 | 2016-12-22 | Rotation Medical, Inc. | Tendon repair implant and method of implantation |
| WO2017011762A1 (en) | 2015-07-16 | 2017-01-19 | Mayo Foundation For Medical Education And Research | Treating rotator cuff conditions |
| WO2017046647A1 (en) | 2015-09-18 | 2017-03-23 | Ortho-Space Ltd. | Intramedullary fixated subacromial spacers |
| US10172703B2 (en) | 2015-10-01 | 2019-01-08 | Arthrex, Inc. | Joint kinematic reconstruction techniques |
| US10813742B2 (en) | 2015-10-01 | 2020-10-27 | Arthrex, Inc. | Joint kinematic reconstruction techniques |
| AU2016344019B2 (en) | 2015-10-30 | 2021-07-15 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Suture sleeve patch and methods of delivery within an existing arthroscopic workflow |
| EP3370698B1 (en) | 2015-11-03 | 2022-01-26 | Zoetis Services LLC | Sol-gel polymer composites and uses thereof |
| CA3008670A1 (en) | 2015-12-31 | 2017-07-06 | Rotation Medical, Inc. | Fastener delivery system and related methods |
| US10314689B2 (en) | 2015-12-31 | 2019-06-11 | Rotation Medical, Inc. | Medical implant delivery system and related methods |
| US11484401B2 (en) | 2016-02-01 | 2022-11-01 | Medos International Sarl | Tissue augmentation scaffolds for use in soft tissue fixation repair |
| US20170273680A1 (en) | 2016-02-01 | 2017-09-28 | DePuy Synthes Products, Inc. | Tissue augmentation tacks for use with soft tissue fixation repair systems and methods |
| US11357495B2 (en) | 2016-02-01 | 2022-06-14 | Medos International Sarl | Tissue augmentation scaffolds for use with soft tissue fixation repair systems and methods |
| US9861410B2 (en) | 2016-05-06 | 2018-01-09 | Medos International Sarl | Methods, devices, and systems for blood flow |
| US10568733B2 (en) | 2017-01-24 | 2020-02-25 | Arthrex, Inc. | Anterior cable region superior capsule reconstructions |
| US11045981B2 (en) | 2017-01-30 | 2021-06-29 | Ortho-Space Ltd. | Processing machine and methods for processing dip-molded articles |
| WO2018144858A1 (en) * | 2017-02-02 | 2018-08-09 | Nanofiber Solutions, Inc. | Methods of improving bone-soft tissue healing using electrospun fibers |
| WO2019033082A1 (en) * | 2017-08-11 | 2019-02-14 | Theracell, Inc. | DEMINERALIZED BONE FIBER COMPOSITION FOR INCREASED FASTENING |
| USD904615S1 (en) * | 2017-10-31 | 2020-12-08 | Sicage Llc | Bone screw |
| EP3720385B1 (en) | 2017-12-07 | 2023-09-27 | Rotation Medical, Inc. | Medical implant delivery system |
| US20200179573A1 (en) * | 2018-12-06 | 2020-06-11 | National Cheng Kung University | Biodegradable metal alloy for anchoring detached tissue to hard tissue, method of making the same, and process for using the same |
| CN113677395A (zh) | 2019-02-13 | 2021-11-19 | 帕萨尔美德他克有限公司 | 用于骨科治疗的植入式电磁场产生器 |
| CN111068116B (zh) * | 2019-12-28 | 2022-03-22 | 河北柯瑞生物医药有限公司 | 一种注射用软骨修复温敏凝胶及其制备方法 |
| US11559330B2 (en) | 2020-02-11 | 2023-01-24 | Embody, Inc. | Surgical cannula with removable pressure seal |
| EP4103106B1 (en) | 2020-02-11 | 2026-03-11 | Embody, Inc. | Implant delivery device |
| AU2021220864B2 (en) | 2020-02-11 | 2024-03-07 | Embody, Inc. | Surgical anchoring device, deployment device, and method of use |
| US11957566B2 (en) * | 2020-02-14 | 2024-04-16 | B/G Ortho Innovations, LLC | Implants and methods for shoulder joint reconstruction |
| CN111346262B (zh) * | 2020-03-17 | 2022-02-01 | 四川大学 | 一种用于促进腱骨愈合的可注射钙磷陶瓷及其制备方法与应用 |
| US12310928B2 (en) | 2020-11-16 | 2025-05-27 | University Of Utah Research Foundation | Enthesis healing |
| CN113633821A (zh) * | 2021-08-18 | 2021-11-12 | 上海交通大学医学院附属第九人民医院 | 一种温敏型可注射型胶原/壳聚糖/掺锌生物玻璃纳米颗粒水凝胶材料及其制备方法 |
| CA3238654A1 (en) * | 2021-11-16 | 2023-05-25 | Mayo Foundation For Medical Education And Research | Methods and compositions for repair of tendon-bone interface |
| US20240261086A1 (en) * | 2023-02-07 | 2024-08-08 | Cannuflow, Inc. | Biological Patch and Fixation Device for Tendon Repair |
| CN121398834A (zh) * | 2023-06-23 | 2026-01-23 | 塞缪尔·E·林奇 | 用于皮肤修复、恢复活性和舒适的方法和组合物 |
Family Cites Families (264)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3943072A (en) | 1971-12-15 | 1976-03-09 | United Kingdom Atomic Energy Authority | Separation of molecules |
| USRE33161E (en) | 1982-04-29 | 1990-02-06 | American Dental Association Health Foundation | Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements |
| NL8402158A (nl) | 1983-07-09 | 1985-02-01 | Sumitomo Cement Co | Poreus keramisch materiaal en werkwijze voor de bereiding daarvan. |
| US4837285A (en) * | 1984-03-27 | 1989-06-06 | Medimatrix | Collagen matrix beads for soft tissue repair |
| US4889919A (en) | 1986-08-13 | 1989-12-26 | Zymogenetics, Inc. | Biologically active PDGF derived A-chain homodimers |
| US5187263A (en) | 1984-10-12 | 1993-02-16 | Zymogenetics, Inc. | Expression of biologically active PDGE analogs in eucaryotic cells |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US5165938A (en) | 1984-11-29 | 1992-11-24 | Regents Of The University Of Minnesota | Wound healing agents derived from platelets |
| US5629191A (en) | 1985-01-03 | 1997-05-13 | Integra Lifesciences Corporation | Method of making a porous matrix particle |
| US5045633A (en) | 1985-02-25 | 1991-09-03 | Zymogenetics, Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US5516896A (en) | 1985-02-25 | 1996-05-14 | Zymogenetics, Inc. | Biologically active B-chain homodimers |
| US5106748A (en) | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| US5108922A (en) | 1986-07-01 | 1992-04-28 | Genetics Institute, Inc. | DNA sequences encoding BMP-1 products |
| US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
| ZA874681B (en) | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
| US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| CA1322714C (en) | 1986-11-14 | 1993-10-05 | Harry N. Antoniades | Wound healing and bone regeneration |
| US5019559A (en) | 1986-11-14 | 1991-05-28 | President And Fellows Of Harvard College | Wound healing using PDGF and IGF-II |
| US5124316A (en) | 1986-11-14 | 1992-06-23 | President And Fellows Of Harvard College | Method for periodontal regeneration |
| DE3785758T2 (de) | 1986-11-14 | 1993-08-05 | Harvard College | Wundheilung und knochenregeneration. |
| US5219759A (en) | 1987-04-22 | 1993-06-15 | Chiron Corporation | Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors |
| US5457093A (en) * | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
| US4874746A (en) | 1987-12-22 | 1989-10-17 | Institute Of Molecular Biology, Inc. | Wound headling composition of TGF-alpha and PDGF |
| US5759815A (en) | 1988-02-11 | 1998-06-02 | Creative Biomolecules, Inc. | Production of platelet derived growth factor (PDGF) an muteins thereof |
| US6586388B2 (en) | 1988-04-08 | 2003-07-01 | Stryker Corporation | Method of using recombinant osteogenic protein to repair bone or cartilage defects |
| US4975526A (en) | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
| US5962028A (en) | 1988-04-20 | 1999-10-05 | Norian Corporation | Carbonated hydroxyapatite compositions and uses |
| US5129905A (en) | 1988-04-20 | 1992-07-14 | Norian Corporation | Methods for in situ prepared calcium phosphate minerals |
| US5053212A (en) | 1988-04-20 | 1991-10-01 | Norian Corporation | Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite |
| US4904259A (en) | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
| US5110604A (en) * | 1988-06-30 | 1992-05-05 | Collagen Corporation | Processes for producing collagen matrixes and methods of using same |
| US5219576A (en) | 1988-06-30 | 1993-06-15 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US5034375A (en) | 1988-08-10 | 1991-07-23 | Institute Of Molecular Biology, Inc. | Process of wound healing using PDGF and EGF |
| US5035887A (en) | 1989-09-07 | 1991-07-30 | Institute Of Moelcular Biology, Inc. | Wound healing composition of IL-1 and PDGF or IGF-1 |
| US5599558A (en) | 1989-09-15 | 1997-02-04 | Curative Technologies, Inc. | Selecting amounts of platelet releasate for efficacious treatment of tissue |
| US5112354A (en) | 1989-11-16 | 1992-05-12 | Northwestern University | Bone allograft material and method |
| US5011910A (en) | 1989-12-28 | 1991-04-30 | Washington University | Reagent and method for determining activity of retroviral protease |
| US5071655A (en) | 1990-01-12 | 1991-12-10 | Baylink David J | Pharmaceutical combination for treatment of bone-wasting diseases |
| JP3159216B2 (ja) * | 1990-02-01 | 2001-04-23 | ユニバーシティ オブ サウス フロリダ | 白血球由来の成長因子 |
| TW199858B (enExample) | 1990-03-30 | 1993-02-11 | Fujirebio Kk | |
| ATE156363T1 (de) | 1990-04-10 | 1997-08-15 | Inst Molecular Biology Inc | Wundheilung |
| DE69132823T2 (de) | 1990-05-16 | 2002-07-18 | Genetics Institute, Inc. | Knochen- und knorpel-bildung hervorrufende proteine |
| EP0564502B1 (en) | 1990-11-27 | 2002-01-30 | The American National Red Cross | Tissue sealant and growth factor containing compositions that promote accelerated wound healing |
| US5853746A (en) | 1991-01-31 | 1998-12-29 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier |
| US5149691A (en) | 1991-03-12 | 1992-09-22 | Creative Biomolecules, Inc. | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
| JPH06500802A (ja) * | 1991-06-14 | 1994-01-27 | アムジエン・インコーポレーテツド | コラーゲンフィルムによるタンパクのドラッグ・デリバリー |
| KR100255415B1 (ko) | 1991-06-25 | 2000-05-01 | 브루스 엠. 에이센 | 비엠피-9 조성물 |
| US5837258A (en) | 1991-08-30 | 1998-11-17 | University Of South Florida | Induction of tissue, bone or cartilage formation using connective tissue growth factor |
| US5270300A (en) | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| DE69233022T2 (de) | 1991-11-04 | 2004-02-12 | Genetics Institute, LLC, Cambridge | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
| AU3062392A (en) | 1991-11-04 | 1993-06-07 | Novo Nordisk A/S | Pdgf gel formulation |
| HU218845B (hu) | 1992-02-12 | 2000-12-28 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh. | Új növekedési/differenciáló faktorokat kódoló DNS-szekvenciák, e faktorokat tartalmazó gyógyszerkészítmények, DNS-molekulák, gazdaszervezetek, antitestek, diagnosztikai eljárások |
| WO1993020859A1 (en) | 1992-04-20 | 1993-10-28 | Board Of Regents Of The University Of Washington | Sustained release compositions for delivery of growth factors |
| IL106278A0 (en) | 1992-07-13 | 1993-11-15 | Sumitomo Metal Ind | Bone formation-inducing protein |
| DK0662146T3 (da) | 1992-09-03 | 2000-11-13 | Univ California | Dorsalvævpåvirkende faktor og præparat |
| EP0690871A4 (en) | 1993-01-12 | 1999-10-20 | Univ Johns Hopkins Med | GROWTH DIFFERENTIATION FACTOR-5 |
| CA2153653C (en) | 1993-01-12 | 2010-12-07 | Se-Jin Lee | Growth differentiation factor-9 |
| EP1475440A3 (en) | 1993-01-12 | 2004-11-17 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-3 |
| ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
| CN1104257C (zh) | 1993-03-29 | 2003-04-02 | 津莫吉尼蒂克斯公司 | 含pdgf和维生素d的刺激成骨细胞生长的组合物 |
| DK0698094T3 (da) | 1993-05-12 | 2004-05-03 | Inst Genetics Llc | BMP-11-sammensætninger |
| DE69433742T2 (de) | 1993-05-12 | 2005-07-07 | Genetics Institute, LLC, Cambridge | Bmp-10 zusammensetzungen |
| AU7205894A (en) | 1993-06-08 | 1995-01-03 | Neogenix, Inc. | Purified natural and synthetic compounds for the treatment of osteoarthritis |
| EP0717633A4 (en) | 1993-07-09 | 1998-05-20 | Univ Johns Hopkins Med | GROWTH DIFFERENTIATION FACTOR-7 |
| CA2165776A1 (en) | 1993-07-09 | 1995-01-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-6 |
| US5531794A (en) | 1993-09-13 | 1996-07-02 | Asahi Kogaku Kogyo Kabushiki Kaisha | Ceramic device providing an environment for the promotion and formation of new bone |
| US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| CA2171546A1 (en) | 1993-10-08 | 1995-04-20 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-10 |
| US5518680A (en) | 1993-10-18 | 1996-05-21 | Massachusetts Institute Of Technology | Tissue regeneration matrices by solid free form fabrication techniques |
| DE69434651T2 (de) | 1993-12-07 | 2007-03-08 | Genetics Institute, Inc., Cambridge | Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen |
| JP3362267B2 (ja) | 1993-12-29 | 2003-01-07 | 日本特殊陶業株式会社 | 生体インプラント材料及びその製造方法 |
| AU704178B2 (en) | 1993-12-30 | 1999-04-15 | Imperial Cancer Research Technology Ltd | Vertebrate embryonic pattern-inducing hedgehog-like proteins |
| US5460962A (en) | 1994-01-04 | 1995-10-24 | Organogenesis Inc. | Peracetic acid sterilization of collagen or collagenous tissue |
| JPH07250688A (ja) | 1994-01-28 | 1995-10-03 | Sagami Chem Res Center | ＴＧＦ−βスーパーファミリー蛋白質をコードするヒト新規ｃＤＮＡ |
| WO1995020967A1 (en) | 1994-02-04 | 1995-08-10 | Cell Therapeutics, Inc. | Composition for wound healing, neuron growth and vascularization |
| US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
| AU1999995A (en) | 1994-04-08 | 1995-11-10 | Atrix Laboratories, Inc. | An adjunctive polymer system for use with medical device |
| AU2297395A (en) | 1994-04-20 | 1995-11-16 | Institute Of Molecular Biology, Inc. | Administration of platelet-derived growth factor and bone seeking drugs for osteoporosis and bone regeneration |
| US7963997B2 (en) | 2002-07-19 | 2011-06-21 | Kensey Nash Corporation | Device for regeneration of articular cartilage and other tissue |
| WO1996001845A1 (en) | 1994-07-08 | 1996-01-25 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-11 |
| CA2195246A1 (en) | 1994-07-13 | 1996-02-01 | Se-Jin Lee | Growth differentiation factor-12 |
| US6180606B1 (en) | 1994-09-28 | 2001-01-30 | Gensci Orthobiologics, Inc. | Compositions with enhanced osteogenic potential, methods for making the same and uses thereof |
| US5651766A (en) | 1995-06-07 | 1997-07-29 | Transfusion Technologies Corporation | Blood collection and separation system |
| AU4137596A (en) | 1994-10-31 | 1996-05-23 | Sepracor, Inc. | Method for the treatment of periodontal disease and a pharmaceutical composition useful in said method |
| US6281332B1 (en) | 1994-12-02 | 2001-08-28 | The Johns Hopkins University School Of Medicine | Hedgehog-derived polypeptides |
| US5635372A (en) | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
| US6541037B1 (en) | 1995-05-19 | 2003-04-01 | Etex Corporation | Delivery vehicle |
| US6287341B1 (en) | 1995-05-19 | 2001-09-11 | Etex Corporation | Orthopedic and dental ceramic implants |
| US6027742A (en) | 1995-05-19 | 2000-02-22 | Etex Corporation | Bioresorbable ceramic composites |
| US5676976A (en) | 1995-05-19 | 1997-10-14 | Etex Corporation | Synthesis of reactive amorphous calcium phosphates |
| ES2293137T3 (es) | 1995-10-11 | 2008-03-16 | Novartis Vaccines And Diagnostics, Inc. | Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas. |
| US5783217A (en) | 1995-11-07 | 1998-07-21 | Etex Corporation | Low temperature calcium phosphate apatite and a method of its manufacture |
| US5747273A (en) | 1996-05-07 | 1998-05-05 | Diagnostic Systems Laboratories, Inc. | Immunoassay of total insulin-like growth factor binding protein-1 |
| AU2759397A (en) | 1996-05-28 | 1998-01-05 | 1218122 Ontario Inc. | Resorbable implant biomaterial made of condensed calcium phosphate particles |
| FR2749756B1 (fr) | 1996-06-14 | 1998-09-11 | Bioland | Procede de preparation d'un materiau composite implantable, materiau obtenu, implant comprenant ce materiau et kit de mise en oeuvre |
| US5965403A (en) | 1996-09-18 | 1999-10-12 | Genetics Institute, Inc. | Nucleic acids encoding bone morphogenic protein-16 (BMP-16) |
| CA2268156C (en) | 1996-10-16 | 2007-05-29 | Etex Corporation | Bioceramic compositions |
| US6037519A (en) | 1997-10-20 | 2000-03-14 | Sdgi Holdings, Inc. | Ceramic fusion implants and compositions |
| DE19646782C2 (de) | 1996-11-13 | 2000-05-25 | Merck Patent Gmbh | Bioresorbierbare Polymerisationsprodukte aus strahlungshärtbaren Bindemittelsystemen |
| WO1998026080A1 (en) | 1996-12-13 | 1998-06-18 | Chiron Corporation | Method for expression of heterologous proteins in yeast |
| US5866165A (en) | 1997-01-15 | 1999-02-02 | Orquest, Inc. | Collagen-polysaccharide matrix for bone and cartilage repair |
| FR2758988B1 (fr) | 1997-02-05 | 2000-01-21 | S H Ind | Procede d'elaboration de substituts osseux synthetiques d'architecture poreuse parfaitement maitrisee |
| EP1350525A3 (en) | 1997-02-07 | 2003-12-10 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods thereof |
| DE69823955T2 (de) | 1997-03-04 | 2005-06-16 | Technology Finance Corp. (Pty.) Ltd., Sandton | Als knochenimplantat geeignetes erzeugnis |
| US20020098222A1 (en) | 1997-03-13 | 2002-07-25 | John F. Wironen | Bone paste |
| US20010016646A1 (en) | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
| US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| JP3334558B2 (ja) * | 1997-04-23 | 2002-10-15 | 富士レビオ株式会社 | 酵素免疫測定方法及び試験片 |
| US20030032586A1 (en) | 1997-05-15 | 2003-02-13 | David C. Rueger | Compositions for morphogen-induced osteogenesis |
| GB2325934A (en) | 1997-06-03 | 1998-12-09 | Polybiomed Ltd | Treating metal surfaces to enhance bio-compatibility and/or physical characteristics |
| US6063624A (en) | 1997-06-09 | 2000-05-16 | Baxter International Inc. | Platelet suspensions and methods for resuspending platelets |
| EP0896825B1 (en) | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
| US6136029A (en) | 1997-10-01 | 2000-10-24 | Phillips-Origen Ceramic Technology, Llc | Bone substitute materials |
| US6090998A (en) | 1997-10-27 | 2000-07-18 | University Of Florida | Segmentally demineralized bone implant |
| WO1999030726A1 (en) | 1997-12-15 | 1999-06-24 | Page Roy C | Improved method for attaching dental and orthopedic implants, ligaments, and tendons to bone |
| US20020018796A1 (en) | 1998-01-28 | 2002-02-14 | John F. Wironen | Thermally sterilized bone paste |
| JP2000004875A (ja) | 1998-06-23 | 2000-01-11 | Teijin Ltd | 増殖因子の産生誘導方法 |
| SE514908C2 (sv) | 1998-07-13 | 2001-05-14 | Gs Dev Ab | Medel för benrekonstruktion |
| PT1100488E (pt) | 1998-07-28 | 2003-09-30 | Synthes Ag | Utilizacao de compostos de creatina para tratamento das celulas e tecidos do osso ou cartilagem |
| US20030114936A1 (en) | 1998-10-12 | 2003-06-19 | Therics, Inc. | Complex three-dimensional composite scaffold resistant to delimination |
| US6224635B1 (en) | 1998-11-06 | 2001-05-01 | Hospital For Joint Diseases | Implantation of surgical implants with calcium sulfate |
| US6663870B2 (en) * | 1998-12-07 | 2003-12-16 | Zymogenetics, Inc. | Methods for promoting growth of bone using zvegf3 |
| US6231528B1 (en) | 1999-01-15 | 2001-05-15 | Jonathan J. Kaufman | Ultrasonic and growth factor bone-therapy: apparatus and method |
| EP1025871A1 (en) | 1999-01-28 | 2000-08-09 | F. Hoffmann-La Roche Ag | Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair |
| ES2209820T3 (es) | 1999-02-04 | 2004-07-01 | Sdgi Holdings, Inc. | Composiciones esponjosas osteogenicas altamente mineralizadas, y usos de las mismas. |
| US6294187B1 (en) | 1999-02-23 | 2001-09-25 | Osteotech, Inc. | Load-bearing osteoimplant, method for its manufacture and method of repairing bone using same |
| US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
| KR20010043639A (ko) | 1999-03-15 | 2001-05-25 | 키이스 디 | 혈소판 수거 시스템 |
| US6296602B1 (en) | 1999-03-17 | 2001-10-02 | Transfusion Technologies Corporation | Method for collecting platelets and other blood components from whole blood |
| ES2199815T3 (es) | 1999-03-19 | 2004-03-01 | The Regents Of The University Of Michigan | Mineralizacion y desarrollo celular supeerficial sobre biomateriales. |
| JP4892133B2 (ja) | 1999-04-12 | 2012-03-07 | ハーベスト・テクノロジーズ・コーポレイション | 血小板富有血漿及び／又は血小板濃縮物を製造する方法 |
| SE515227C2 (sv) | 1999-04-28 | 2001-07-02 | Bruce Medical Ab | Kropp för åstadkommande av in- och tillväxt av benvävnad och/ eller bindväv och sätt för framställning av kroppen |
| US6468543B1 (en) * | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| US6710025B1 (en) * | 1999-05-26 | 2004-03-23 | The Brigham And Women's Hospital, Inc. | Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin |
| AU5444800A (en) | 1999-05-27 | 2000-12-18 | Research Foundation Of State University Of New York, The | LTiGTin vitroLT/iGT cell culture device including cartilage and methods of usingthe same |
| DE19926083A1 (de) | 1999-06-08 | 2000-12-14 | Universitaetsklinikum Freiburg | Biologisches Gelenkkonstrukt |
| US20040059416A1 (en) * | 1999-06-22 | 2004-03-25 | Murray Martha M. | Biologic replacement for fibrin clot |
| US6964685B2 (en) * | 1999-06-22 | 2005-11-15 | The Brigham And Women's Hospital, Inc. | Biologic replacement for fibrin clot |
| US6429013B1 (en) | 1999-08-19 | 2002-08-06 | Artecel Science, Inc. | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair |
| DE19940717A1 (de) | 1999-08-26 | 2001-03-01 | Gerontocare Gmbh | Resorblerbares Knochenersatz- und Knochenaufbaumaterial |
| US6280191B1 (en) * | 1999-09-03 | 2001-08-28 | Christopher B. Gordon | Distractor suitable for permanent implantation into bone |
| WO2001032197A2 (en) | 1999-11-02 | 2001-05-10 | Eli Lilly And Company | Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders |
| US6451059B1 (en) | 1999-11-12 | 2002-09-17 | Ethicon, Inc. | Viscous suspension spinning process for producing resorbable ceramic fibers and scaffolds |
| AU1622801A (en) | 1999-11-18 | 2001-05-30 | Regents Of The University Of Michigan, The | Sustained drug delivery from structural matrices |
| US7887551B2 (en) | 1999-12-02 | 2011-02-15 | Smith & Nephew, Inc. | Soft tissue attachment and repair |
| WO2001041822A1 (en) | 1999-12-09 | 2001-06-14 | Biosyntech Canada Inc. | Mineral-polymer hybrid composition |
| US6479418B2 (en) | 1999-12-16 | 2002-11-12 | Isotis N.V. | Porous ceramic body |
| US20030103960A1 (en) | 1999-12-22 | 2003-06-05 | Pierre Philippart | Sealant and bone generating product |
| CA2396016A1 (en) | 1999-12-29 | 2001-07-05 | Andy Bernhardt | System for reconstituting pastes and methods of using same |
| AU4234901A (en) | 2000-01-28 | 2001-08-07 | Dot Dunnschicht Und Oberflache | Inorganic resorbable bone substitute material and production method |
| WO2001057083A1 (en) | 2000-02-04 | 2001-08-09 | Zymogenetics, Inc. | Methods for promoting growth of bone, ligament, and cartilage using zvegf4 |
| JP2001217440A (ja) * | 2000-02-04 | 2001-08-10 | Kanegafuchi Chem Ind Co Ltd | ハイブリッド型薄膜光電変換装置とそれに用いられる透光性積層体 |
| AU2001241594A1 (en) | 2000-02-18 | 2001-08-27 | Regeneration Technologies, Inc. | Implantable tissues infused with growth factors and other additives |
| IT1316769B1 (it) | 2000-02-18 | 2003-05-12 | Getters Spa | Pannello evacuato per isolamento termico con ridotta conduzione dicalore ai bordi |
| US7022506B2 (en) | 2000-02-23 | 2006-04-04 | The Trustees Of The University Of Pennsylvania | Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee |
| CA2401421A1 (en) | 2000-03-03 | 2001-09-13 | Smith & Nephew, Inc. | Shaped particle and composition for bone deficiency and method of making the particle |
| US20030055511A1 (en) | 2000-03-03 | 2003-03-20 | Schryver Jeffrey E. | Shaped particle comprised of bone material and method of making the particle |
| ES2272452T3 (es) * | 2000-03-09 | 2007-05-01 | Zimmer Orthobiologics, Inc. | Producto de anclaje biologico de tejido conectivo al hueso. |
| AU784377B2 (en) | 2000-03-14 | 2006-03-23 | Arthur V. Sampaio | Compositions and methods for affecting osteogenesis |
| US20020006437A1 (en) | 2000-05-01 | 2002-01-17 | Grooms Jamie M. | Non-migration tissue capsule |
| US20020022885A1 (en) | 2000-05-19 | 2002-02-21 | Takahiro Ochi | Biomaterial |
| AU2001262605A1 (en) | 2000-05-19 | 2001-11-26 | Europrint Holdings Limited | Method and system for implementing a game |
| US7081240B1 (en) | 2000-06-28 | 2006-07-25 | Zimmer Orthobiologics, Inc. | Protein mixtures for wound healing |
| CN1471412B8 (zh) | 2000-06-29 | 2016-06-15 | 生物合成技术加拿大公司 | 用于修复和再生软骨和其它组织的组合物以及该组合物的用途 |
| DK177997B1 (da) | 2000-07-19 | 2015-02-23 | Ed Geistlich Söhne Ag Für Chemische Ind | Knoglemateriale og collagenkombination til opheling af beskadigede led |
| US6877735B2 (en) * | 2000-07-19 | 2005-04-12 | F&F Limited | Paper sheet managing device and recording system |
| US6739112B1 (en) | 2000-08-21 | 2004-05-25 | Nu Vasive, Inc. | Bone allograft packaging system |
| GB0020610D0 (en) | 2000-08-21 | 2000-10-11 | Dytech Corp Ltd | Uses of porous carriers |
| US6585730B1 (en) | 2000-08-30 | 2003-07-01 | Opus Medical, Inc. | Method and apparatus for attaching connective tissues to bone using a knotless suture anchoring device |
| US6773723B1 (en) * | 2000-08-30 | 2004-08-10 | Depuy Acromed, Inc. | Collagen/polysaccharide bilayer matrix |
| JP2004512145A (ja) | 2000-10-31 | 2004-04-22 | デピュイ・アクロメッド・インコーポレイテッド | 骨および軟骨の修復用の鉱物質化したコラーゲン−多糖類型基質 |
| US20020127265A1 (en) * | 2000-12-21 | 2002-09-12 | Bowman Steven M. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
| CA2365376C (en) * | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
| US7192604B2 (en) | 2000-12-22 | 2007-03-20 | Ethicon, Inc. | Implantable biodegradable devices for musculoskeletal repair or regeneration |
| JP2004533276A (ja) | 2001-01-25 | 2004-11-04 | リジェネレーション テクノロジーズ インク． | 注射可能な多孔性骨グラフト材料 |
| US7005135B2 (en) | 2001-01-30 | 2006-02-28 | Ethicon Inc. | Glass scaffolds with controlled resorption rates and methods for making same |
| US20020169122A1 (en) | 2001-02-23 | 2002-11-14 | Wyeth | Chondrogenic potential of human bone marrow-derived CD105+ cells by BMP |
| US6743232B2 (en) | 2001-02-26 | 2004-06-01 | David W. Overaker | Tissue scaffold anchor for cartilage repair |
| US6575986B2 (en) | 2001-02-26 | 2003-06-10 | Ethicon, Inc. | Scaffold fixation device for use in articular cartilage repair |
| US6949251B2 (en) | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
| US20030049328A1 (en) | 2001-03-02 | 2003-03-13 | Dalal Paresh S. | Porous beta-tricalcium phosphate granules and methods for producing same |
| WO2002102783A1 (en) | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US20030109537A1 (en) | 2001-07-09 | 2003-06-12 | Turner Russell T. | Methods and materials for treating bone conditions |
| AU2002316694B2 (en) * | 2001-07-16 | 2007-09-06 | Depuy Products, Inc. | Hybrid biologic/synthetic porous extracellular matrix scaffolds |
| CA2460026C (en) | 2001-09-24 | 2011-06-28 | Millenium Biologix Inc. | Porous ceramic composite bone grafts |
| DE60224822T2 (de) * | 2001-10-19 | 2009-01-22 | Zymogenetics, Inc., Seattle | Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung |
| US6649072B2 (en) | 2001-11-16 | 2003-11-18 | Robert Brandt | Method for producing autologous platelet-rich plasma |
| AU2002365969A1 (en) | 2001-11-20 | 2003-06-10 | Scott Bruder | Flowable osteogenic and chondrogenic compositions |
| US7045105B2 (en) | 2001-12-21 | 2006-05-16 | Lagow Richard J | Calcium phosphate bone replacement materials and methods of use thereof |
| US20030180344A1 (en) | 2002-02-05 | 2003-09-25 | Cambridge Scientific, Inc. | Bioresorbable osteoconductive compositions for bone regeneration |
| AU2003210996A1 (en) | 2002-02-11 | 2003-09-04 | Zymogenetics, Inc. | Materials and methods for preparing dimeric growth factors |
| US7879107B2 (en) | 2002-02-20 | 2011-02-01 | The Cleveland Clinic Foundation | Composition and method for inducing bone growth and healing |
| DK175356B1 (da) | 2002-02-28 | 2004-09-06 | Coloplast As | Stomiindretning |
| JP3739715B2 (ja) | 2002-03-19 | 2006-01-25 | オリンパス株式会社 | 人工骨および組織工学用担体 |
| KR100460685B1 (ko) | 2002-04-10 | 2004-12-09 | 재단법인서울대학교산학협력재단 | 인산칼슘계 화합물을 이용한 인공 골 충진재 및 그 제조방법 |
| AU2003228587A1 (en) * | 2002-04-18 | 2003-11-03 | University Of Florida | Biomimetic organic/inorganic composites, processes for their production, and methods of use |
| CA2485090A1 (en) * | 2002-05-02 | 2003-12-24 | Osteoscreen, Inc. | Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates (no-bisphosphonate) |
| US20040033949A1 (en) | 2002-05-06 | 2004-02-19 | Genentech, Inc. | Use of VEGF for treating bone defects |
| US7368125B2 (en) | 2002-06-05 | 2008-05-06 | Ethicon, Inc. | Amphiphilic polymers for medical applications |
| US7041309B2 (en) | 2002-06-13 | 2006-05-09 | Neuropro Technologies, Inc. | Spinal fusion using an HMG-CoA reductase inhibitor |
| CA2432583A1 (en) | 2002-06-20 | 2003-12-20 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Method of preparing alpha- and beta-tricalcium phosphate powders |
| US20040002770A1 (en) | 2002-06-28 | 2004-01-01 | King Richard S. | Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof |
| ES2242916T3 (es) | 2002-07-11 | 2005-11-16 | Biomet Deutschland Gmbh | Metodos de preparacion de segmentos y granulos de fosfato de calcio poroso mediante procesamiento con gelatina. |
| US7744651B2 (en) | 2002-09-18 | 2010-06-29 | Warsaw Orthopedic, Inc | Compositions and methods for treating intervertebral discs with collagen-based materials |
| EP1563846B1 (en) | 2002-10-10 | 2012-08-29 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production promoters |
| US20040078090A1 (en) | 2002-10-18 | 2004-04-22 | Francois Binette | Biocompatible scaffolds with tissue fragments |
| US7824701B2 (en) * | 2002-10-18 | 2010-11-02 | Ethicon, Inc. | Biocompatible scaffold for ligament or tendon repair |
| AU2003203316B2 (en) | 2003-02-13 | 2007-01-11 | Synthes Gmbh | Injectable bone-replacement mixture |
| US20040230309A1 (en) | 2003-02-14 | 2004-11-18 | Depuy Spine, Inc. | In-situ formed intervertebral fusion device and method |
| WO2004078069A2 (en) | 2003-03-05 | 2004-09-16 | Therics, Inc. | Process for manufacturing biomedical articles by infiltrating biocompatible metal alloys in porous matrices |
| US20040193270A1 (en) | 2003-03-31 | 2004-09-30 | Depuyacromed, Inc. | Implantable bone graft |
| US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
| KR20060031808A (ko) | 2003-06-11 | 2006-04-13 | 오스테오테크, 인코포레이티드 | 뼈 임플란트 및 그의 제조 방법 |
| US6974862B2 (en) | 2003-06-20 | 2005-12-13 | Kensey Nash Corporation | High density fibrous polymers suitable for implant |
| ATE396669T1 (de) | 2003-06-24 | 2008-06-15 | Robert Mathys Foundation Dr H | Prothesenvorrichtung zur wiederherstellung von knorpel |
| DE10328892A1 (de) | 2003-06-26 | 2005-05-12 | Curasan Ag | Knochenaufbaumittel und Herstellungsverfahren |
| ES2564044T3 (es) | 2003-06-27 | 2016-03-17 | DePuy Synthes Products, Inc. | Células posparto derivadas de tejido del cordón umbilical y métodos de preparación y uso de las mismas |
| FI20031120A0 (fi) | 2003-07-31 | 2003-07-31 | Bci Bioabsorbable Concepts Ltd | Monifunktionaalinen implanttilaite |
| US7163920B2 (en) | 2003-09-30 | 2007-01-16 | Ethicon, Inc. | Peptide with osteogenic activity |
| CU23352A1 (es) | 2003-10-16 | 2009-03-16 | Centro Nacional De Investigaciones Cientificas | Biomateriales compuestos para implantes óseos |
| NZ547140A (en) * | 2003-10-22 | 2009-09-25 | Encelle Inc | Bioactive hydrogel compositions in dehydrated form for regenerating connective tissue |
| US20050098915A1 (en) * | 2003-11-07 | 2005-05-12 | Smith & Nephew Inc. | Manufacture of bone graft substitutes |
| WO2005065079A2 (en) | 2003-11-10 | 2005-07-21 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
| MXPA06005358A (es) | 2003-11-14 | 2006-07-10 | Univ Pennsylvania | Metodo y aparato para el tratamiento de la osteoartritis, enfermedades de los cartilagos, defectos y lesiones en la cadena humana. |
| DE10355559A1 (de) | 2003-11-21 | 2005-06-23 | Orthogen Ag | Transskin |
| EP1537839A1 (en) | 2003-12-02 | 2005-06-08 | Dr. h. c. Robert Mathys Foundation | Prosthetic device for cartilage repair |
| WO2005072656A1 (en) | 2004-01-27 | 2005-08-11 | Osteotech, Inc. | Stabilized bone graft |
| US7189263B2 (en) * | 2004-02-03 | 2007-03-13 | Vita Special Purpose Corporation | Biocompatible bone graft material |
| US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
| US7671012B2 (en) | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
| US7928059B2 (en) | 2004-02-24 | 2011-04-19 | Wisconsin Alumni Research Foundation | Use of neuropeptides for traumatic cartilage injury |
| KR101013999B1 (ko) | 2004-03-19 | 2011-02-14 | 재단법인서울대학교산학협력재단 | 표면에 골조직 형성 증진 펩타이드가 고정된 차폐막 및임플란트 |
| US20070190101A1 (en) | 2004-03-31 | 2007-08-16 | Chunlin Yang | Flowable bone grafts |
| WO2006031388A2 (en) | 2004-08-20 | 2006-03-23 | Hyperbranch Medical Technology, Inc. | Dentritic polymers, crosslinked gels, and their uses in orthopedic applications |
| CN101084025A (zh) | 2004-09-14 | 2007-12-05 | 新加坡科技研究局 | 多孔生物材料－填充物复合物及其制造方法 |
| CN101060821A (zh) | 2004-09-21 | 2007-10-24 | 麻省理工学院 | 梯度支架及其制备方法 |
| US7473678B2 (en) * | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| US7250550B2 (en) | 2004-10-22 | 2007-07-31 | Wright Medical Technology, Inc. | Synthetic bone substitute material |
| WO2006050493A2 (en) | 2004-11-03 | 2006-05-11 | The Regents Of The University Of Michigan | Biodegradable implant for intertransverse process fusion |
| WO2007008250A2 (en) | 2004-12-07 | 2007-01-18 | Gelwell Biotech Corporation | Biomaterials for guided tissue regeneration and target drug delivery |
| US20060151383A1 (en) | 2005-01-12 | 2006-07-13 | Aaf-Mcquay Inc. | Pleated corrugated media and method of making |
| US7621963B2 (en) | 2005-04-13 | 2009-11-24 | Ebi, Llc | Composite bone graft material |
| US8268344B2 (en) * | 2005-04-27 | 2012-09-18 | The Regents Of The University Of Michigan | Particle-containing complex porous materials |
| EP1909810B2 (en) | 2005-06-07 | 2017-08-23 | The Regents of the University of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival |
| US20060287676A1 (en) * | 2005-06-15 | 2006-12-21 | Rita Prajapati | Method of intra-operative coating therapeutic agents onto sutures, composite sutures and methods of use |
| WO2007061889A2 (en) | 2005-11-17 | 2007-05-31 | Biomimetic Therapeutics, Inc. | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
| US7749555B2 (en) | 2006-01-25 | 2010-07-06 | Medtronic, Inc | Modification of chemical forces of bone constructs |
| WO2007090102A2 (en) | 2006-01-27 | 2007-08-09 | The Regents Of The University Of California | Biomimetic scaffolds |
| US20070178159A1 (en) | 2006-01-30 | 2007-08-02 | Alza Corporation | In-Situ Forming Porous Scaffold |
| EP1991282B1 (en) * | 2006-02-09 | 2013-06-19 | BioMimetic Therapeutics, LLC | Compositions and methods for treating bone |
| US7833270B2 (en) | 2006-05-05 | 2010-11-16 | Warsaw Orthopedic, Inc | Implant depots to deliver growth factors to treat osteoporotic bone |
| WO2007133451A1 (en) | 2006-05-08 | 2007-11-22 | Nuvasive, Inc. | Cancellous bone treated with collegenase and essentially free of blood cells |
| US9161967B2 (en) * | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| CA2656278C (en) | 2006-06-30 | 2016-02-09 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating rotator cuff injuries |
| US8106008B2 (en) * | 2006-11-03 | 2012-01-31 | Biomimetic Therapeutics, Inc. | Compositions and methods for arthrodetic procedures |
| WO2008086486A1 (en) | 2007-01-10 | 2008-07-17 | The Regents Of The University Of Michigan | Porous objects having immobilized encapsulated biomolecules |
| WO2008103690A2 (en) | 2007-02-20 | 2008-08-28 | Biomimetic Therapeutics, Inc. | Prevention and treatment for osteonecrosis and osteoradionecrosis of the jaw using pdgf and a bone matrix |
| CN101820895A (zh) | 2007-06-04 | 2010-09-01 | 生物模拟治疗公司 | 用于治疗脊柱的组合物和方法 |
| CA2690457C (en) | 2007-06-15 | 2018-02-20 | Osteotech, Inc. | Bone matrix compositions and methods |
| WO2009042514A1 (en) | 2007-09-25 | 2009-04-02 | Integra Lifesciences Corporation | Flowable wound matrix and its preparation and use |
| KR20110067035A (ko) | 2008-09-09 | 2011-06-20 | 바이오미메틱 세라퓨틱스, 인크. | 건 및 인대 손상의 치료를 위한 혈소판-유래 성장 인자 조성물 및 방법 |
| BRPI0923015A2 (pt) | 2008-12-19 | 2015-12-15 | Biomimetic Therapeutics Inc | enxertos ósseos com atividade de protease reduzida e métodos de seleção e uso |
| AU2010221089A1 (en) * | 2009-03-05 | 2011-09-15 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects |
| MX2017004520A (es) | 2014-10-14 | 2018-03-15 | Lynch Samuel | Composiciones para tratar heridas. |
-
2007
- 2007-07-02 CA CA2656278A patent/CA2656278C/en not_active Expired - Fee Related
- 2007-07-02 AU AU2007269712A patent/AU2007269712B2/en not_active Ceased
- 2007-07-02 WO PCT/US2007/015345 patent/WO2008005427A2/en not_active Ceased
- 2007-07-02 EP EP07796636.4A patent/EP2049145B1/en not_active Not-in-force
- 2007-07-02 EP EP18157933.5A patent/EP3381463A1/en not_active Withdrawn
- 2007-07-02 JP JP2009518331A patent/JP5484047B2/ja not_active Expired - Fee Related
- 2007-07-02 ES ES07796636.4T patent/ES2664229T3/es active Active
- 2007-07-02 US US11/772,646 patent/US9642891B2/en active Active
-
2017
- 2017-03-31 US US15/476,394 patent/US20170202920A1/en not_active Abandoned
-
2018
- 2018-06-13 US US16/007,476 patent/US20180360914A1/en not_active Abandoned
- 2018-06-13 US US16/007,486 patent/US10456450B2/en active Active
-
2021
- 2021-11-24 US US17/535,050 patent/US20220160835A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180360914A1 (en) | 2018-12-20 |
| WO2008005427A2 (en) | 2008-01-10 |
| US9642891B2 (en) | 2017-05-09 |
| WO2008005427A3 (en) | 2008-08-07 |
| US20180360915A1 (en) | 2018-12-20 |
| EP2049145B1 (en) | 2018-03-14 |
| CA2656278A1 (en) | 2008-01-10 |
| EP2049145A2 (en) | 2009-04-22 |
| US10456450B2 (en) | 2019-10-29 |
| US20220160835A1 (en) | 2022-05-26 |
| AU2007269712A1 (en) | 2008-01-10 |
| EP3381463A1 (en) | 2018-10-03 |
| AU2007269712B2 (en) | 2013-02-07 |
| CA2656278C (en) | 2016-02-09 |
| JP5484047B2 (ja) | 2014-05-07 |
| US20170202920A1 (en) | 2017-07-20 |
| JP2009542681A (ja) | 2009-12-03 |
| US20080027470A1 (en) | 2008-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10456450B2 (en) | Compositions and methods for treating rotator cuff injuries | |
| CN102231992B (zh) | 用于治疗肌腱和韧带损伤的血小板衍生生长因子的组合物和方法 | |
| ES2848562T3 (es) | Procedimiento indirecto para reparación de tejido articular | |
| US8106008B2 (en) | Compositions and methods for arthrodetic procedures | |
| CA2819258C (en) | Compositions and methods for spine fusion procedures | |
| JP2012519556A (ja) | 骨軟骨欠損を治療するための血小板由来増殖因子組成物および方法 | |
| CN105854074B (zh) | 用于牵引成骨术的组合物和方法 | |
| AU2013203295A1 (en) | PDGF-biomatrix compositions and methods for treating rotator cuff injuries | |
| HK1131746A (en) | Pdgf-biomatrix compositions and methods for treating rotator cuff injuries | |
| HK1131746B (en) | Pdgf-biomatrix compositions and methods for treating rotator cuff injuries | |
| AU2017213462A1 (en) | Compositions and methods for spine fusion procedures |